AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 27 - (NewsRx.com & NewsRx.net) -- Quidel Corporation announced that the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS) issued its Final Rule for Medicare National Coverage for Collagen Crosslinks, a rapid point-of-care (POC) diagnostic test, marketed by Quidel under the tradename Metra DPD.
As a result of this Final Rule, Medicare will cover and reimburse for the Metra DPD test for primary and secondary osteoporosis associated with 22 disease classifications, subject to the guidelines described in the Rule.
Metra DPD is intended to identify elevated bone resorption that is associated with osteoporosis and other metabolic bone diseases, in both women and men. Metra DPD is intended for use as an aid in monitoring patient response to hormonal and bisphosphonate therapies and in individuals diagnosed with osteoporosis.
"National Medicare coverage for Metra DPD is a significant step forward in making this test available and financially practical for Medicare beneficiaries who take anti-resorptive medications and whose physicians want to monitor bone resorption changes," said S. Wayne Kay, Quidel. "Although some Medicare carriers have reimbursed for the test, other carriers previously denied coverage. This coverage policy establishes mandatory national Medicare coverage for Metra DPD for women and men who are diagnosed with primary or secondary osteoporosis."
Nelson Watts, MD, president of the International Society for Clinical Densitometry and Director of the University of Cincinnati Bone Health and Osteoporosis Center, Ohio said, "I am pleased that Medicare has taken this step to establish a national coverage policy for collagen crosslinks. The assay is clinically useful in the management of patients being treated for primary or secondary osteoporosis. Since this national coverage policy sets the parameters for all Medicare carriers to cover and reimburse for the test, it benefits patients covered by Medicare nationwide."
According to the National Osteoporosis Foundation, osteoporosis is a serious medical condition that threatens 28 million Americans, 10 million of whom have osteoporosis and another 18 million who have low ...
Source: HighBeam Research, Test Gains Mandatory National Medicare Coverage.(Collagen Crosslinks...